#IVOST
Kot da se ljubezn(ivost)i v sLOVEniji neprijazno odrekajo v imenu panoptičnega nadzora, sumničavosti in oblastnosti.
June 21, 2026 at 8:31 PM
IVOST - I vost. IV to oral switch of treatment. I had no idea!
May 22, 2026 at 7:47 AM
Scale and spread of our metronidazole #GoGreen #IVOST grassroots #QI initiative in @nhsggc.bsky.social
A triple win for our #patients, #healthcare & #environment 👇

#Sustainability #Netzero 🌍 #Everydosecounts 💉➡️💊

@sushealthcare.bsky.social
@minnaeii.bsky.social

doi.org/10.1093/jaca...
Validate User
doi.org
September 18, 2025 at 7:07 AM
AS QI initiatives for IV to oral switch (IVOST) show CO₂e savings in plastic waste. Savings per dose range from 1.61 to 7.62 kg CO₂e. A pragmatic approach aids in measuring environmental impact. 🌍💊##idsky
P32 A pragmatic quality improvement ‘good enough’ approach to measuring and comparing carbon-footprint savings associated with ‘Go Green’ switching from IV to oral therapy (IVOST) or reducing IV dose frequency
Antimicrobial stewardship (AS) quality improvement (QI) initiatives promoting IV to oral switch (IVOST)1 or reduced IV dosing frequency provide benefits for patients, staff and the environment.2,3 To determine if initiatives are effective, we need to measure if improvement has occurred. Measuring carbon-footprint savings can be challenging due to lack of available information on the environmental impact of pharmaceutical products and the time needed to complete a thorough environment impact calculation. Consequently, more pragmatic ‘good enough’ QI indicator measures need to be developed to enable improvement in the environmental impact of QI initiatives promoting reduced IV use to be more easily measured and compared.4 One such approach would be to remove drug and reconstitution products from the calculation5 and focus on the equipment commonalities used in the standard process of peripheral IV administration. This approach enables standardized indicator measures for carbon-footprint savings in terms of plastic waste reduction to be developed.ObjectivesTo measure the carbon-footprint saving associated with switching from peripheral IV to solid oral administration in terms of plastic waste reduction and use this to develop standard indicator measures for calculating carbon-footprint savings associated with IVOST or reduced IV dosing frequency.MethodsUsing process mapping the core administration equipment for common peripheral IV dosing schedules was collated over a 72 h period in line with local policy for replacement of peripheral lines. A hybrid carbon foot-printing methodology was used to estimate the carbon-footprint of peripheral IV and oral medicine administration in terms of carbon dioxide equivalent (CO2e) emissions.6,7 Emissions associated with the IV and oral pharmaceutical products were excluded. A process-based approach was used to estimate emissions of the syringe, cannula, safety needle and oral medicine plastic pot using emission factors taken from the UK government carbon conversion factors database6. In addition, an environmentally extended input output analysis (EEIOA) was used to estimate the emissions associated with alcohol wipes, saline solution, IV3000, Octopus 2 and Volumat Line using the medical instrument conversion factor taken from the 20/21 Greener NHS database. Emissions associated with non-sterile gloves and aprons were taken from a previously published report7.ResultsThis pragmatic approach enabled CO2e savings in terms of plastic waste reduction for IVOST of common IV dosing schedules to be calculated irrespective of the drug administered (Table 1). This methodology also enabled CO2e savings to be calculated and compared between different drugs when switching from IV to oral administration at the same/different dosing frequency or when switching from higher frequency (e.g. 4-6 times daily) to lower frequency (once or twice daily) IV regimens (Tables 1 and 2) or to extended interval IV regimens given weekly or monthly.ConclusionsTaking a pragmatic ‘good enough’ approach to measuring improvement in carbon-footprint savings associated with IVOST enabled standard indicator CO2e savings in terms of plastic waste reduction to be calculated. This is important in supporting more efficient, straightforward and comparable measurement of carbon-footprint savings from AS QI initiatives promoting IVOST or switching from higher to lower frequency dosing schedules of different drugs. Table 1.Comparison of the carbon footprint of common peripheral IV dosing schedules and savings of IVOST in terms of plastic waste reductionAdministration scheduleIVKgCO2e per doseOralKgCO2e per doseKgC02e saving per IVOST doseKgCO2e saving per IVOST dayOnce daily dosing1.62350.00671.61681.6168Twice daily dosing1.41560.00671.40892.8178Three times daily dosing1.34680.00671.34014.0203Four times daily dosing1.31220.00671.30555.2220Six times daily dosing1.27770.00671.27107.6260Calculations exclude drug and reconstitution products.  Table 2.Examples of comparison of the carbon footprint savings in terms of plastic waste reduction of peripheral IVOST of different dosing frequency regimens or reducing IV dosing frequencyChange in administration regimenKgCO2e saving per daySix times daily IV flucloxacillin switched to ONCE daily IV daptomycin6.0427 (1.2777 × 6) − 1.6235Twice daily IV vancomycin switched to BD oral linezolid2.8178 (1.4156 × 2) − (0.0067 × 2)Four times daily piperacillin/tazobactam switched to TDS oral co-amoxiclav5.2287 (1.3122 × 4) − (0.0067 × 3)Three times daily IV meropenem switched to ONCE daily IV ertapenem2.4169 (1.3468 × 3) − (1.6235)Calculations exclude drug and reconstitution products.
academic.oup.com
July 16, 2025 at 3:30 AM
📉 33% reduction in metronidazole DDDs/1000 OBDs; 46% fewer IV doses (5250/month). 💰 £60k saved annually; 21k nursing hours saved. 🌍 93.3 tonnes CO2e reduced yearly.##idsky
P24 Scale and spread of a metronidazole ‘Go Green’ IV to oral switch (IVOST) grassroots quality improvement initiative in Scotland’s largest acute health board
Promoting appropriate IV to oral switch (IVOST)1 is a fundamental antimicrobial stewardship (AS) initiative providing benefits for patients, staff and the environment including: reduced risk of cannula related infections, medicine costs, nursing workload and carbon footprint.1,2 A grassroots quality improvement (QI) initiative, highlighting the high oral bioavailability (>90%) of metronidazole and environmental benefits of IVOST in surgical wards at the Royal Alexandra Hospital (RAH), resulted in a 45% median reduction in IV administrations.3 Scale and spread of successful small scale QI initiatives,4 although challenging in the complex healthcare environment, is essential to maximize patient benefits and support attainment of national targets for antimicrobial resistance (AMR)5 and environmental sustainability.6ObjectivesThis study set out to scale and spread the QI initiative promoting metronidazole IVOST to all acute hospitals in NHSGGC, the largest acute health board in Scotland, and measure the impact on AS, drug costs, nursing workload and environmental sustainability.MethodsA QI scale and spread approach was used including the following. Eye catching posters displayed in key ward areas/electronic guideline platform. Electronic prescribing (HEPMA) IVOST prompts displayed when prescribing or administering IV metronidazole. ‘Think tabs before jags’ blog7 was used to highlight the initiative widely. HEPMA targeted prospective audit/feedback and antimicrobial ward round review of patients prescribed IV metronidazole. Multidisciplinary staff champions and Antibiotic Guardian ‘Gold Star’ awards were used to promote staff engagement. Regular feedback to medical, nursing and pharmacy teams via update reports and hospital governance committees. Oral and IV metronidazole usage data was calculated at baseline and for 40 months ‘post change’. Improvement measures in terms of reduced IV administrations, drug costs and nursing time saved8 were calculated. Plastic waste reduction (giving sets, single use plastics, cannula, safety needles, gloves and aprons) associated with IVOST was calculated in terms of carbon dioxide equivalent (CO2e) emissions using a hybrid carbon foot-printing methodology and emissions factor databases.9ResultsA 33% median reduction in total (IV plus oral) metronidazole defined daily doses (DDDs) per 1000 occupied bed days (OBDs) (Figure 1). A 46% median reduction in IV metronidazole DDDs/1000 OBDs (Figure 2), equating to 5250 and 63 000 fewer IV administrations monthly and annually, respectively. Equivalent nursing time saved equating to 1750 h per month and 21 000 h per year. A 37% (£60 000) annual reduction in metronidazole drug cost. The carbon footprint saving achieved from metronidazole IVOST was calculated as 1.48111 KgCO2e per dose equating to 7775 KgCO2e per month and an annual carbon footprint saving of 93.3 tonnes CO2e.ConclusionsA QI scale and spread approach, to raise awareness of the multidisciplinary team to the high oral bioavailability of metronidazole and benefits of appropriate IVOST, resulted in a change in prescribing behaviour and a significant reduction in IV administrations. The initiative also resulted in a sustained reduction in total metronidazole use across NHSGGC acute hospitals. This is important in terms of improved AS, patient safety, workforce cost and efficiency and environmental sustainability. Crucially these results support attainment of national targets for tackling AMR5 and the climate emergency.6  Figure 1.Total metronidazole (IV+ oral) DDDs per 1000 OBDs.  Figure 2.IV metronidazole and oral metronidazole DDDs per 1000 OBDs.
academic.oup.com
July 15, 2025 at 7:30 AM
Wait until you learn about IVOST too 🤣
November 13, 2024 at 1:11 AM